AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7491550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast reduction group (cigarettes with a tar yield of about half their usual brand)
Number of subjects: 434
Study 7491550 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow reduction group (reduced to the same level in steps over several months)
Number of subjects: 434
Study 7491550 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued smoking cigarettes with a tar yield 10% lower than their usual brand)
Number of subjects: 434
Study 2022713 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily metGH (0.043 mg/kg)
Number of subjects: 20
Study 2022713 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times per week metGH (0.1 mg/kg)
Number of subjects: 20
Study 2022713 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (combined data)
Number of subjects: 20
Study 2022713 — intervention group
Group type: COMPARATOR
Intervention: Daily metGH
Number of subjects: 20
Study 2022713 — intervention group
Group type: COMPARATOR
Intervention: Three times per week metGH
Number of subjects: 20
Study 7075659 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine (a selective 5‐HT uptake inhibitor) administered for 3 days
Number of subjects: 0
Study 7075659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30456814 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based personalized feedback, psychoeducation tailored to personal symptom profile, information about available mental health services.
Number of subjects: 1374
Study 30456814 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 1374
Study 28328802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral macroporous resin hemoperfusion (experiment 1 group)
Number of subjects: 90
Study 28328802 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral macroporous resin hemoperfusion (experiment 2 group)
Number of subjects: 90
Study 28328802 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 25297946 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in polluted air
Number of subjects: 25
Study 25297946 — intervention group
Group type: COMPARATOR
Intervention: Ambient air exposure
Number of subjects: 25
Study 23830290 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 19
Study 23830290 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise (MICE)
Number of subjects: 19
Study 21925203 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cardiovascular prevention program executed by a health advisor
Number of subjects: 1275
Study 19016317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 32
Study 19016317 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 32
Study 17570880 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention (nurse care manager counseling, problem identification, care planning)
Number of subjects: 197
Study 17570880 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (comprehensive evaluation of diabetes)
Number of subjects: 197
Study 17570880 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention with more than 2 contacts with the study nurse
Number of subjects: 197
Study 17570880 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention with less than 2 contacts with the study nurse
Number of subjects: 197
Study 15456080 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day)
Number of subjects: 63
Study 15456080 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b (1.5 microg/kg weekly) plus ribavirin (1000-1200mg per day) plus amantadine (200 mg per day)
Number of subjects: 63
Study 15456080 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alpha-2b plus ribavirin
Number of subjects: 63
Study 11521804 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMP (bleomycin, vindesine, mitomycin-C, and cisplatin)
Number of subjects: 201
Study 11521804 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (P)
Number of subjects: 201
Study 11521804 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMP
Number of subjects: 201
Study 9921605 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliprodil (a non‐competitive NMDA receptor antagonist)
Number of subjects: 452
Study 9921605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 452
Study 7646310 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 5 mg/day (N = 37)
Number of subjects: 115
Study 7646310 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril 1.25 mg/day (N = 38)
Number of subjects: 115
Study 7646310 — intervention group
Group type: COMPARATOR
Intervention: placebo (N = 40)
Number of subjects: 115
Study 2656362 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuresis
Number of subjects: 19
Study 2656362 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic paracentesis
Number of subjects: 19
Study 5067672 — intervention group
Group type: EXPERIMENTAL
Intervention: Horlicks (hot, bedtime, milk-cereal drink)
Number of subjects: 18
Study 5067672 — intervention group
Group type: COMPARATOR
Intervention: Inert capsule (control)
Number of subjects: 18
Study 30916589 — intervention group
Group type: EXPERIMENTAL
Intervention: PELD combined with postoperative three-dimensional traction
Number of subjects: 180
Study 30916589 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 180
Study 30916589 — intervention group
Group type: COMPARATOR
Intervention: PELD
Number of subjects: 180
Study 28764999 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25226826 — intervention group
Group type: EXPERIMENTAL
Intervention: Echium oil (10 g daily providing 1.2 g of SDA)
Number of subjects: 36
Study 25226826 — intervention group
Group type: COMPARATOR
Intervention: HOSO (high oleic acid sunflower oil)
Number of subjects: 36
Study 23055142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror image pointing with right arm to left shoulder
Number of subjects: 0
Study 23055142 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded pointing
Number of subjects: 0
Study 21646672 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-specific factors affecting blood pressure treatment
Number of subjects: 788
Study 19199498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium infusion
Number of subjects: 108
Study 19199498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose magnesium infusion
Number of subjects: 108
Study 19199498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose magnesium infusion
Number of subjects: 108
Study 19199498 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 108
Study 16762750 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved LVEF (≥45%)
Number of subjects: 141
Study 16762750 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced LVEF (<45%)
Number of subjects: 141
Study 16762750 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 141
Study 16762750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm with normal LV filling pattern
Number of subjects: 141
Study 16762750 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial arrhythmias
Number of subjects: 141
Study 15544588 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 5 mg/day (2.5 mg/day for children ≤24 months of age)
Number of subjects: 412
Study 15544588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 15544588 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 412
Study 11021338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (pain induced)
Number of subjects: 41
Study 9315059 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleet enemas
Number of subjects: 102
Study 9315059 — intervention group
Group type: COMPARATOR
Intervention: Picolax
Number of subjects: 102
Study 8333747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubenimex
Number of subjects: 258
Study 8333747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 3365283 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine (50 mg/d for initial treatment, 150 mg/d for maintenance)
Number of subjects: 12
Study 3365283 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine (50 mg/d and 150 mg/d)
Number of subjects: 12
Study 3365283 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (1 g/kg)
Number of subjects: 12
Study 3365283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31277077 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC)
Number of subjects: 30
Study 31277077 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 30
Study 31189238 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment combined with TCM syndrome differentiation
Number of subjects: 160
Study 31189238 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 160
Study 29180210 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-Z (neoadjuvant chemotherapy + zoledronic acid)
Number of subjects: 188
Study 29180210 — intervention group
Group type: COMPARATOR
Intervention: CT (neoadjuvant chemotherapy)
Number of subjects: 188
Study 26165236 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic Airway Laryngopharyngeal Tube (S.A.L.T.)
Number of subjects: 120
Study 26165236 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 120
Study 23248342 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamwork Intervention (TI)
Number of subjects: 48
Study 23248342 — intervention group
Group type: COMPARATOR
Intervention: Asthma Education (AE)
Number of subjects: 48
Study 23248342 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 48
Study 21979284 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 60
Study 21979284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18289334 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg thrice weekly (on Monday, Wednesday, and Saturday) for the first month, 250 mg thrice weekly for the second month, and 250 mg twice weekly for the third month.
Number of subjects: 67
Study 18289334 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg/day for three months.
Number of subjects: 67
Study 20687917 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised allergy training for healthcare professionals
Number of subjects: 230
Study 20687917 — intervention group
Group type: COMPARATOR
Intervention: Usual care by healthcare professionals
Number of subjects: 230
Study 15598198 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based self-help manuals and sessions with an interactive computer program
Number of subjects: 393
Study 15598198 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based self-help manuals
Number of subjects: 393
Study 15598198 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 393
Study 12117042 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education with 4-hour schooling and individual consultations
Number of subjects: 62
Study 12117042 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 9537607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (15 mg orally twice a day for 5 days)
Number of subjects: 20
Study 9537607 — intervention group
Group type: COMPARATOR
Intervention: Control group (isoenergetic diet without dexfenfluramine)
Number of subjects: 20
Study 9537607 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 20
Study 9537607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 8018756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensure HN (a complete, defined, pre-prepared low-fibre diet) for four days and two cleansing enemas the evening prior to the operation
Number of subjects: 18
Study 8018756 — intervention group
Group type: COMPARATOR
Intervention: Five days of residue-free hospital meals, cleansing enemas, laxatives, and three litres of polyethylene glycol solution
Number of subjects: 18
Study 2688491 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg)
Number of subjects: 12
Study 2688491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 790558 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg subcutaneously)
Number of subjects: 12
Study 790558 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 12
Study 30668243 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP plus 8.5% doxycycline hyclate gel
Number of subjects: 34
Study 30668243 — intervention group
Group type: COMPARATOR
Intervention: CRP alone
Number of subjects: 34
Study 30668243 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP plus 2% clindamycin hydrochloride gel
Number of subjects: 34
Study 29776987 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-μg subcutaneous glucagon (MDG)
Number of subjects: 15
Study 29776987 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% basal insulin reduction
Number of subjects: 15
Study 29776987 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-g oral glucose tablets
Number of subjects: 15
Study 29776987 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 15
Study 26610183 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock wave therapy (rESWT) with nightly splinting
Number of subjects: 34
Study 26610183 — intervention group
Group type: COMPARATOR
Intervention: Sham rESWT with nightly splinting
Number of subjects: 34
Study 25102684 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Taohongsiwu decoction (soaked for 30 min, once daily)
Number of subjects: 0
Study 25102684 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine (100 mg orally, twice daily)
Number of subjects: 0
Study 21833673 — intervention group
Group type: EXPERIMENTAL
Intervention: Huperzine A (0.1‐mg bid)
Number of subjects: 78
Study 21833673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vitamin C 100‐mg bid)
Number of subjects: 78
Study 19195847 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (RLAI)
Number of subjects: 1622
Study 19195847 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotics (AP)
Number of subjects: 1622
Study 17595037 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive pressure support ventilation (NI-PSV) with 7.9 ± 1.3 cm H2O above NCPAP pressure support
Number of subjects: 15
Study 17595037 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) at 5.3 ± 0.6 cm H2O
Number of subjects: 15
Study 14727274 — intervention group
Group type: EXPERIMENTAL
Intervention: Midfemoral block (group MF)
Number of subjects: 63
Study 14727274 — intervention group
Group type: COMPARATOR
Intervention: Lateral sciatic nerve block (group PB)
Number of subjects: 63
Study 11152919 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated estrogens plus 2.5 mg of medroxyprogesterone acetate in one tablet daily (n = 768)
Number of subjects: 1525
Study 11152919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 757)
Number of subjects: 1525
Study 9589285 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Management (BFM) model
Number of subjects: 26
Study 9589285 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist competency and adherence ratings
Number of subjects: 26
Study 7990242 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training exercises 2 days per week (n = 20)
Number of subjects: 40
Study 7990242 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (n = 19)
Number of subjects: 40
Study 2657027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin pastille 200,000 units
Number of subjects: 24
Study 2657027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin pastille 400,000 units
Number of subjects: 24
Study 2657027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29769054 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in organised social activities
Number of subjects: 1028
Study 29769054 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at religious activities
Number of subjects: 1028
Study 29769054 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual factors associated with social participation
Number of subjects: 1028
Study 29769054 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to social participation
Number of subjects: 1028
Study 28269767 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 83
Study 28269767 — intervention group
Group type: COMPARATOR
Intervention: Galantamine
Number of subjects: 83
Study 25639148 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation e-cigarettes
Number of subjects: 22
Study 25639148 — intervention group
Group type: COMPARATOR
Intervention: First-generation e-cigarettes
Number of subjects: 22
Study 23992601 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 16492
Study 23992601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16492
Study 21038765 — intervention group
Group type: EXPERIMENTAL
Intervention: All Stars Challenge intervention
Number of subjects: 0
Study 21038765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 18219129 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIg treatment guided by RT‐PCR
Number of subjects: 75
Study 18219129 — intervention group
Group type: COMPARATOR
Intervention: IVIg treatment guided by viral isolation
Number of subjects: 75
Study 18219129 — intervention group
Group type: EXPERIMENTAL
Intervention: RT‐PCR positive for enterovirus
Number of subjects: 75
Study 18219129 — intervention group
Group type: COMPARATOR
Intervention: RT‐PCR negative for enterovirus
Number of subjects: 75
Study 16797429 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 120
Study 16797429 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 120
Study 12022784 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge (ESD)
Number of subjects: 82
Study 12022784 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 82
Study 10050217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine with low bypass flow rate
Number of subjects: 100
Study 10050217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine with high bypass flow rate
Number of subjects: 100
Study 10050217 — intervention group
Group type: COMPARATOR
Intervention: Saline with low bypass flow rate
Number of subjects: 100
Study 10050217 — intervention group
Group type: COMPARATOR
Intervention: Saline with high bypass flow rate
Number of subjects: 100
Study 8526158 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fatty tissue transplantation
Number of subjects: 400
Study 8526158 — intervention group
Group type: COMPARATOR
Intervention: Nearby control crease (no intervention)
Number of subjects: 400
Study 2317174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal vibration at 2.0 Hz
Number of subjects: 16
Study 2317174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal vibration at 2.5 Hz
Number of subjects: 16
Study 2317174 — intervention group
Group type: EXPERIMENTAL
Intervention: Random vibration at 2.0 Hz
Number of subjects: 16
Study 2317174 — intervention group
Group type: EXPERIMENTAL
Intervention: Random vibration at 2.5 Hz
Number of subjects: 16
Study 2317174 — intervention group
Group type: EXPERIMENTAL
Intervention: Collimated display at frequencies above 1.6 Hz
Number of subjects: 16
Study 2317174 — intervention group
Group type: COMPARATOR
Intervention: Non-collimated display at frequencies above 1.6 Hz
Number of subjects: 16
Study 523424 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholintheophyllinate (Euspirax) 400 mg
Number of subjects: 12
Study 523424 — intervention group
Group type: COMPARATOR
Intervention: Theophyllin‐Aethylendiamine (Euphyllin retard) 350 mg
Number of subjects: 12
Study 31559418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 4859
Study 31559418 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education
Number of subjects: 4859
Study 28711361 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow Flexed (EF) crutch setup
Number of subjects: 30
Study 28711361 — intervention group
Group type: COMPARATOR
Intervention: Elbow Extended (EE) crutch setup
Number of subjects: 30
Study 26975890 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) delivered via facial mask (inspiratory pressure support level, 5‐15 cm H2O; positive end‐expiratory pressure, 5‐10 cm H2O; fraction of inspired oxygen titrated to maintain SpO2 ≥94%) (n=148)
Number of subjects: 293
Study 26975890 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (up to 15 L/min to maintain SpO2 of 94% or higher) (n=145)
Number of subjects: 293
Study 26975890 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 293
Study 26975890 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 293
Study 24719249 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant bacteriuria (6.5% of samples)
Number of subjects: 247
Study 23964144 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mL of NaP (prep 1)
Number of subjects: 349
Study 23964144 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mL of NaP + 20 mg of bisacodyl (prep 2)
Number of subjects: 349
Study 23964144 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L of PEG (prep 3)
Number of subjects: 349
Study 23964144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L of PEG + 20 mg of bisacodyl (prep 4)
Number of subjects: 349